GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ananda Pharma PLC (STU:1FX) » Definitions » Other Gross PPE

Ananda Pharma (STU:1FX) Other Gross PPE : €1.74 Mil (As of Jul. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Ananda Pharma Other Gross PPE?

Ananda Pharma's Other Gross PPE for the quarter that ended in Jul. 2024 was €1.74 Mil.

Ananda Pharma's quarterly Other Gross PPE increased from Jan. 2023 (€0.49 Mil) to Jul. 2023 (€1.94 Mil) but then declined from Jul. 2023 (€1.94 Mil) to Jul. 2024 (€1.74 Mil).

Ananda Pharma's annual Other Gross PPE stayed the same from Jan. 2021 (€0.00 Mil) to Jan. 2022 (€0.00 Mil) but then increased from Jan. 2022 (€0.00 Mil) to Jan. 2023 (€0.49 Mil).


Ananda Pharma Other Gross PPE Historical Data

The historical data trend for Ananda Pharma's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ananda Pharma Other Gross PPE Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23
Other Gross PPE
- - - - 0.49

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jul24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.49 1.94 1.74

Ananda Pharma Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Ananda Pharma Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is focused on the development of cannabinoid therapies for the treatment of a range of complex conditions. The company is developing NHS-approved and MHRA-licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure.

Ananda Pharma Headlines

No Headlines